Restart Life Sciences Corp.
Restart Life Sciences Corp. (NMLSF) Revenue
Annual & quarterly revenue history · segment & region breakdown
NMLSF · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsRestart Life Sciences Corp. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | +$0.00B | +59.51% |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Restart Life Sciences Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Restart Life Sciences Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Restart Life Sciences Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NMLSF revenue · 4 questionsNMLSF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Restart Life Sciences Corp. SEC filings · GAAP · Restart Life Sciences Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026